Dead Sea Scrolls much older than previously thought, AI-based study finds
Scientists from the University of Groningen in the Netherlands utilized artificial intelligence to examine the handwriting of the ancient fragments and claim they derived more accurate dates for some writings, including the Book of Daniel, according to a paper published in Plos One.
A part of the Isaiah Scroll, one of the Dead Sea Scrolls, is seen inside the vault of the Shrine of the Book building at the Israel Museum in Jerusalem.
Getty Images
The aptly named AI program 'Enoch' was fed a plethora of already dated ancient texts from modern-day Israel and the West Bank that also had radiocarbon dates — then used machine learning to study the handwriting progressions of 135 Dead Sea Scroll fragments.
Advertisement
The study claimed that the fragment of the Book of Daniel 8-11, which was thought to be dated to 160s BC, could be as old as 230 BC, which overlaps with the period in which the biblical book was authored.
'With the Enoch tool we have opened a new door into the ancient world, like a time machine, that allows us to study the hands that wrote the Bible,' the study's authors wrote in a statement, Eureka Alert reported.
'Especially now that we have established, for the first time, that two biblical scroll fragments come from the time of their presumed authors,' the statement continued.
Advertisement
A 2,000-year-old fragment from the Dead Sea Scrolls on display at The Jewish Museum in New York City in 2008.
Getty Images
Researchers also claim that fragments written in Herodian Aramaic and Hasmonaean Hebrew — considered to have emerged in the First and Second centuries BC — are actually older than initially thought and provide a new lens for the presumed proliferation of writing during that era.
These new dating claims result in 'a new chronology of the scrolls and the re-dating of ancient Jewish key texts that contribute to current debates on Jewish and Christian origins,' the study stated.
Advertisement
The Dead Sea Scrolls were first discovered in 1943 by two Bedouin shepherds who found them secreted in caves in the Qumran section of Israel near the Dead Sea and are the oldest known fragments of Jewish manuscripts written in Hebrew, Greek, Arabic and Aramaic dating back to the Third and Second century BC.
Scholars attribute the trove of religious manuscripts to the Essens, who were Jewish sectarians at the turn of the first millennium.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
6 hours ago
- Newsweek
Breakthrough Nanobody Tech Hits Lung Cancer Cells Like a Drone Strike
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A nanobody-based technology can precisely identify and attack lung cancer cells—sparing surrounding healthy tissue. This is the promise of researchers at the Bio-Nano Research Center at the Korea Research Institute of Bioscience and Biotechnology (KRIBB), who say that the approach could improve cancer therapy by reducing harmful side effects and maximizing efficiency. The study showed treatment potential for lung adenocarcinoma—a type of non-small cell lung cancer—in particular. This is the most common type of lung cancer seen in the U.S., accounting for 45 percent of all cases in 2021, according to the Centers for Disease Control and Prevention (CDC). Lung adenocarcinoma often has late detection and high recurrence rates after treatment. Mature man in pain coughing on sofa at home. Mature man in pain coughing on sofa at home. brizmaker/Getty Images Current chemotherapies can attack healthy cells, fail to deliver drugs precisely to cancer cells and lead to side effects. With this in mind, the team developed the 'A5 nanobody'—a tiny antibody that binds to a protein called CD155 found in high abundance on lung cancer cells. The A5 nanobody is around 10 times smaller than conventional antibodies, helping it to penetrate deep into tissues. Crucially, it can bind selectively to cancer cells, leading to a reduction of more than 50 percent in components of cancer spread. The researchers also engineered a drug delivery system called A5-LNP-DOX, which combines the A5 nanobody with liposomal capsules containing the anticancer drug doxorubicin (DOX). This design acts like a "drone strike," delivering the drug precisely to CD155 targets on the surface of cancer cells, according to the researchers. Pink visual of lung cancer adenocarcinoma cells. Pink visual of lung cancer adenocarcinoma cells. rightdx/Getty Images In the study, A5-LNP-DOX delivered up to three times more drug into cancer cells than conventional methods, significantly enhancing cancer cell death while leaving healthy cells largely unharmed, the researchers found. Tests in animal models and patient-derived organoids showed tumor size reductions of 70–90 percent and substantial increases in cancer cell death markers. Meanwhile, no damage was detected in major organs including the liver, heart or kidneys. "Our study presents a new therapeutic strategy capable of precisely targeting cancer cells and delivering drugs effectively," said study author Juyeon Jung in a statement. "We expect this nanobody-based approach to serve as a versatile platform for treating not only lung cancer but also a variety of other cancers, contributing greatly to the advancement of precision medicine." Newsweek has reached out to the researchers for comment. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about lung cancer? Let us know via health@ Reference Noh, K., Yi, S., Kim, H., Lee, J., Kim, S., Yoo, W., Jung, E., Choi, J., Park, H., Hwang, S., Kang, J. Y., Park, K.-H., Park, H., Lee, Y., Lim, E.-K., Kang, T., & Jung, J. (2025). Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery. Signal Transduction and Targeted Therapy, 10(1), 218.
Newsweek
7 hours ago
- Newsweek
Coffee May Hide Secret to Diabetes Management
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Compounds found in coffee beans could offer a new way to help people living with diabetes manage their condition. Three compounds in particular have demonstrated significant inhibitory effects on α-glucosidase, a key enzyme in carbohydrate digestion. This could lead to new functional food ingredients targeting type 2 diabetes, according to the study by the Kunming Institute of Botany in China. Around 1 in 10 Americans (more than 38 million people) live with diabetes, of which 90–95 percent have type 2. This occurs when insulin doesn't work properly or there's not enough of it. Current management methods include checking blood sugar (or glucose) levels and keeping them close to a personal target level to prevent or delay complications. Healthy eating, being active and getting enough sleep may be enough to help manage the condition in some circumstances, or doctors may prescribe metformin, insulin or other medicines (along with lifestyle factors). Coffee beans in the hand's of a worker. Coffee beans in the hand's of a worker. Schwede-Photodesign/Getty Images Building on this, the new study shows promising anti-diabetic potential and helps to expand our understanding of coffee's functional components, according to the researchers. Functional foods are known for both their nutritional value and for delivering "biologically active" compounds with potential health benefits, like antioxidant, neuroprotective, or glucose-lowering properties. "Coffee diterpenes are a class of characteristic components in coffee, which have potential biological activities including the prevention of cancer, obesity, diabetes, and other diseases," the researchers wrote in their paper. "Due to the complex chemical composition of roasted coffee beans, analyzing the composition and potential activity of coffee diterpenes has always been a challenge." To solve this, scientists have been trying more advanced techniques called nuclear magnetic resonance (NMR) and liquid chromatography–mass spectrometry (LC-MS/MS) to speed up the discovery of the bioactive molecules, as found in "chemically diverse" systems like roasted coffee. "Functional food ingredients could potentially help with managing glucose, in principle. But for an ingredient to be useful, we need to know the effective dose, safety, and bioavailability in humans," Signe Svanfeldt, lead nutritionist at Lifesum, told Newsweek. "Many promising lab results never translate into practical benefits. So, while functional ingredients may support glucose management, they are always adjuncts to diet, activity, and medication—not replacements." In this study, the team developed a three-step, activity-oriented strategy to efficiently identify bioactive diterpene esters in roasted coffee arabica beans. Arabica is the most popular of four main types of coffee beans, alongside Robusta, Liberica and Excelsa. "The study isolated specific molecules from coffee beans, not brewed coffee itself. Normal coffee consumption has previously been linked in large population studies to a lower risk of developing type 2 diabetes and better survival in people with diabetes. Both regular and decaf coffee show this, suggesting compounds beyond caffeine are beneficial," said Svanfeldt. The scientists' goal was to discover both abundant and trace-level compounds with α-glucosidase inhibitory activity, while minimizing the use of solvents and analysis time. "The structures of the three new compounds were determined through comprehensive spectral analysis," the researchers wrote. The new isolated diterpene esters were named caffaldehydes A, B, and C. In the study, these compounds, differing in their fatty acid chains, showed a moderate α-glucosidase inhibitory activity with values more potent than the control drug acarbose. Acarbose is sometimes used to help people with type 2 diabetes when changes to diet, or other medications have been unable to bring down blood sugar levels to their target range. It slows down the digestion of starchy foods like potatoes, pasta and rice from the gut, meaning blood sugar levels rise more slowly after meals. "To explore trace active diterpene esters of the same type in coffee, a molecular network based on LC-MS/MS was constructed, and three novel coffee diterpene esters were identified," the authors added. These three additional unknown compounds were closely related to caffaldehydes A–C, sharing "common fragment ions but featuring different fatty acids". Their absence in compound databases confirmed their novelty. The findings demonstrate the effectiveness of this approach in discovering structurally diverse, biologically relevant compounds in complex food matrices (structures and interactions) like roasted coffee, according to the study. It could also pave the way to developing new functional food ingredients or nutraceuticals derived from coffee, targeting glucose regulation and potentially aiding in diabetes management. Happy mature woman checking blood sugar level at home with monitor. Happy mature woman checking blood sugar level at home with monitor. stefanamer/Getty Images "The new compounds in this paper are not proven to have effects in humans yet. Drinking coffee is fine as part of a healthy lifestyle, but it shouldn't be seen as a treatment for diabetes," said Svanfeldt. The researchers also said the strategy used in their study could be adapted for rapid screening of bioactive metabolites in other complex food matrices. Next steps will include exploring the biological activity of the newly identified trace diterpenes and assessing their safety and efficacy in vivo. While Svanfeldt said, if developed further, these findings would most likely lead to an "add-on to standard care", she emphasized: "Coffee, or these compounds, cannot replace CGMs, glucose testing, medications, or lifestyle measures. "Caffeine tolerance is highly individual. While up to 400mg of caffeine per day—about three to four cups of brewed coffee, is generally considered safe for most healthy adults, some may experience side effects such as anxiety, sleep disturbances, or gastrointestinal discomfort at lower levels." Newsweek has reached out to the researchers for additional comment. Do you have a tip on a health story that Newsweek should be covering? Do you have a question type 2 diabetes? Let us know via health@ Reference Hu, G., Quan, C., Al-Romaima, A., Dai, H., Qiu, M., Hu, G., Quan, C., Al-Romaima, A., Dai, H., & Qiu, M. (2024). Bioactive oriented discovery of diterpenoids in Coffea arabica basing on 1D NMR and LC-MS/MS molecular network. Beverage Plant Research, 5(1).
Yahoo
9 hours ago
- Yahoo
Using AI Made Doctors Worse at Spotting Cancer Without Assistance
Credit - Getty Images Health practitioners, companies, and others have for years hailed the potential benefits of AI in medicine, from improving medical imaging to outperforming doctors at diagnostic assessments. The transformative technology has even been predicted by AI enthusiasts to one day help find a 'cure to cancer.' But a new study has found that doctors who regularly used AI actually became less skilled within months. The study, which was published on Wednesday in the Lancet Gastroenterology and Hepatology journal, found that over the course of six months, clinicians became over-reliant on AI recommendations and became themselves 'less motivated, less focused, and less responsible when making cognitive decisions without AI assistance.' It's the latest study to demonstrate potential adverse outcomes on AI users. An earlier study by the Massachusetts Institute of Technology found that ChatGPT eroded critical thinking skills. How the study was conducted Researchers across various European institutions conducted an observational study surveying four endoscopy centers in Poland that participated in the Artificial Intelligence in Colonoscopy for Cancer Prevention (ACCEPT) trial. The study was funded by the European Commission and Japan Society for the Promotion of Science. As part of the trial, the centers had introduced AI tools for the detection of polyps—growths that can be benign or cancerous—in late 2021. The study looked at 1,443 non-AI-assisted colonoscopies out of a total 2,177 colonoscopies conducted between September 2021 and March 2022. The colonoscopies were performed by 19 experienced endoscopists. Researchers compared the quality of colonoscopy conducted three months before and three months after AI was implemented. Colonoscopies were conducted either with or without AI assistance, at random. Of those conducted without AI assistance, 795 were conducted before regular AI use was implemented and 648 were conducted after the AI tools were introduced. What the study found Three months before AI was introduced, the adenoma detection rate (ADR) was around 28%. Three months after AI was introduced, the rate dropped to 22% when clinicians were unassisted by AI. ADR is a commonly used quality indicator for colonoscopies and represents 'the proportion of screening colonoscopies performed by a physician that detect at least one histologically confirmed colorectal adenoma or adenocarcinoma.' Adenomas are precancerous growths, and a higher ADR is associated with a lower risk of colorectal cancer. The study found that AI did help endoscopists with detection when used, but once the assistance was removed, clinicians were worse at detection. Researchers attributed it to 'the natural human tendency to over-rely' on the recommendations of decision support systems like AI. 'Imagine that you want to travel anywhere, and you're unable to use Google Maps,' Marcin Romańczyk, co-author of the study and an assistant professor at the Medical University of Silesia, told MedPage Today. 'We call it the Google Maps effect. We try to get somewhere, and it's impossible to use a regular map. It works very similarly.' Implications of the study Omer Ahmad, a consultant gastroenterologist at University College Hospital London who wrote an editorial alongside the study but was not involved in its research, tells TIME that it's likely that exposure to AI weakened doctors' visual search habits and alerting gaze patterns, which are critical for detecting polyps. 'In essence, dependence on AI detection could dull human pattern recognition,' Ahmad says. He adds that regular use of AI could also 'reduce diagnostic confidence' when AI assistance is withdrawn, or that the endoscopists' skill of manoeuvring the colonoscope could be reduced. In comments to the Science Media Center (SMC), Catherine Menon, principal lecturer at the University of Hertfordshire's Department of Computer Science, said: 'Although de-skilling resulting from AI use has been raised as a theoretical risk in previous studies, this study is the first to present real-world data that might potentially indicate de-skilling arising from the use of AI in diagnostic colonoscopies.' Menon raised concerns that overreliance on AI could leave health practitioners at risk to technological compromise. Other experts are more cautious about drawing conclusions from a single study. Venet Osmani, a professor of clinical AI and machine learning at Queen Mary University of London, noted to SMC that the total number of colonoscopies—including both AI-assisted and non-AI-assisted ones—increased over the course of the study. The increased workload, Osmani suggested, could have led to clinician fatigue and poorer detection rates. Allan Tucker, a professor of artificial intelligence at Brunel University of London, also noted that with AI assistance, clinician performance improved overall. Concerns about deskilling due to automation bias, added Tucker to SMC, 'is not unique to AI systems and is a risk with the introduction of any new technology.' 'The ethical question then is whether we trust AI over humans,' said Tucker. 'Often, we expect there to be a human overseeing all AI decision-making but if the human experts are putting less effort into their own decisions as a result of introducing AI systems this could be problematic.' 'This is not simply about monitoring technology,' says Ahmad. 'It's about navigating the complexities of a new human-AI clinical ecosystem.' Establishing safeguards is critical, he adds, suggesting that beyond this study, people may need to focus on 'preserving essential skills in a world where AI becomes ubiquitous.' Contact us at letters@
